

ANTICANCER ACTIVE INGREDIENT DERIVED FROM GUIERA SENEGALENSIS



A
Guiera senegalensis is a very common plant in tropical Africa. Sahelian Species [soudano], its zones of abundance are mainly in in West Africa. This plant is very common in the Sahel where it forms specific mono settlements.

B, This table below describes anti- proliferative activities for 3 different actives principles (tamoxifène, 5-FU et Guieranone B), on the same breast cancerous cells MCF-7, with the same laboratory condition. The CI50 (half maximal inhibitory concentration) observed for Guieranon B (7.09µM) is between tamoxifen and 5-FU values. Thus Guieranon B could be an interesting active principle for breast cancer treatment.

	CI50 average µg/mL	CI50 average µM
Tamoxifen	4,42 ± 0,24	11,91 ± 0,93
5-FU	0,53 ± 0,05	4,04 ± 0,39
Guieranon B	2,24 ± 0,13	7,09 ± 0,41

PATENT

FR2980196
WO2013037964

INVENTORS

Chalard Pierre,
Caldefie-Chezet Florence,
Delort Laetitia,
Patel Kirti

LABORATORY

Human Nutrition Unit
Team: CELLular miCro-enviRonment,
Immunomodulation and Nutrition

VISIT US:



Institute of Chemistry of Clermont-Ferrand
Team: Design and Synthesis of Analgesic
Molecules (CESMA)

VISIT US:



PROBLEM

One recognizes mainly in *Guiera senegalensis* the properties anti-inflammatory drugs, disinfectants, bechic, diuretic, eupneic and febrifuge. From where its regulation for cough, the states dyspneic, paludism, pneumopathies, the bronchopathies. In Fact the sheets are generally used in the form of decocte or macerated in bath and like drink. In external use, *Guiera senegalensis* is regarded as vulnerary disinfectant, healing for the treatment of the wounds, the stomatites, gum diseases, of the chancres. A methoxylate naphthyl butenone, called Guieranone A, was isolated from the sheets of *Guiera senegalensis*. Guieranon A has Naphtyl Butenone from the Leaves of *Guiera senegalensis* with Antifungal Activity.

TECHNOLOGICAL SOLUTION

The inventors could isolate a new compound starting from *Guiera senegalensis*, Guieranon B. This new compound usable as pharmaceutical active ingredient, in particular in the treatment of cancer, and can be presented in the form of an extract of plant concentrated or in the form of composed of synthesis.

The inventors moreover discovered that this compound presents a high antiproliferative activity, as that was shown on line of cells cancerous mammary MCF- 7. An object of the invention is thus to propose Guieranon B like new compound or pharmaceutical active ingredient, in particular like new anti-cancer agent.

APPLICATIONS

- For parenteral administration, intravenous routes in prostate, breast and colon cancers.

CURRENT STAGE OF DEVELOPMENT

- Maturation in progress

AVAILABLE FOR LICENSING

OPPORTUNITY: License and exploitation - Look for collaborative research
CONTACT : Business developper - Solène Vallin - solene.vallin@udamail.fr